New molecular entities: erlotinib, solifenacin, natalizumab

News
Article

New molecular entities: erlotinib, solifenacin, natalizumab

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!
Recent Videos
Related Content
FDA Approves First in Class Therapy for Hereditary Angioedema

FDA Approves First in Class Therapy for Hereditary Angioedema

Denise Myshko
August 23rd 2025
Article

Read More

MedImpact To Offer Unbranded Ustekinumab-aekn Biosimilar

MedImpact To Offer Unbranded Ustekinumab-aekn Biosimilar

Logan Lutton
August 23rd 2025
Article

Read More

ryanking999-stock.adobe.com

FDA Set Review Date for Imcivree for Rare Form of Obesity

Denise Myshko
August 23rd 2025
Article

Read More

Jim Vallee-stock@adobe.com

Medicare Patients Face Higher Drug Costs Despite $2,000 Spending Cap

Denise Myshko
August 23rd 2025
Article

Read More

FDA Approves Tonmya for Adult Fibromyalgia

FDA Approves Tonmya for Adult Fibromyalgia

Logan Lutton
August 23rd 2025
Article

Read More

Matt Fowler KC-stock@adobe.com

FDA Grants Accelerated Approval of Wegovy to Treat Liver Disease

Denise Myshko
August 23rd 2025
Article

Read More

© 2025 MJH Life Sciences

All rights reserved.